Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE -39.1%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $195M | $425M | $674M | $499M | $423M | $535M | — | — |
| Enterprise Value | $156M | $386M | $632M | $499M | $404M | $243M | — | — |
| P/E Ratio → | -1.32 | — | 10.29 | — | — | — | — | — |
| P/S Ratio | 49.10 | 16.73 | 3.20 | 3.87 | — | — | — | — |
| P/B Ratio | 0.68 | 1.39 | 1.57 | 2.06 | 1.99 | 1.79 | — | — |
| P/FCF | — | — | — | 3.72 | — | — | — | — |
| P/OCF | — | — | — | 3.57 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.18 | 3.00 | 3.87 | — | — | — | — |
| EV / EBITDA | — | — | 12.45 | — | — | — | — | — |
| EV / EBIT | — | — | 9.51 | 41.42 | — | — | — | — |
| EV / FCF | — | — | — | 3.72 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.9% | 83.9% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | -613.7% | -613.7% | 22.3% | -2.5% | — | — | — | — |
| Net Profit Margin | -565.5% | -565.5% | 31.1% | -5.2% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -39.1% | -39.1% | 19.6% | -2.9% | -37.0% | -39.8% | — | — |
| ROA | -31.8% | -31.8% | 13.2% | -1.9% | -33.9% | -29.3% | -85.9% | -25.5% |
| ROIC | -35.8% | -35.8% | 11.2% | -1.1% | -72.6% | — | — | — |
| ROCE | -37.2% | -37.2% | 11.8% | -1.2% | -36.8% | -30.1% | -94.4% | -72.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.14 | 0.28 | 0.12 | — | — | — |
| Debt / EBITDA | — | — | 1.17 | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | -0.10 | 0.00 | -0.09 | -0.97 | — | — |
| Net Debt / EBITDA | — | — | -0.83 | — | — | — | — | — |
| Debt / FCF | — | — | — | 0.00 | — | — | — | — |
| Interest Coverage | — | — | — | — | -34.95 | — | — | — |
Net cash position: cash ($90M) exceeds total debt ($51M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.53 | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Quick Ratio | 12.53 | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Cash Ratio | 12.09 | 12.09 | 10.64 | 2.22 | 8.59 | 43.32 | 11.62 | 8.77 |
| Asset Turnover | — | 0.07 | 0.40 | 0.27 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 37.00 | 6.37 | 16.63 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 9.7% | — | — | — | — | — |
| FCF Yield | — | — | — | 26.9% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $41M | $39M | $33M | $31M | $31M | $31M | $1M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TRDA stock.
Entrada Therapeutics, Inc.'s current P/E ratio is -1.3x. The historical average is 10.3x.
Entrada Therapeutics, Inc.'s return on equity (ROE) is -39.1%. The historical average is -19.9%.
Based on historical data, Entrada Therapeutics, Inc. is trading at a P/E of -1.3x. Compare with industry peers and growth rates for a complete picture.
Entrada Therapeutics, Inc. has 83.9% gross margin and -613.7% operating margin.
Key Metrics
Top Statement Risk
Runway vs. immaterial revenue base
Metrics are mathematically derived from official filings.
Asset Discount Masks Revenue Evaporation
TRDA trades at 0.65x book yet 7.39x sales, a divergence suggesting the market is pricing the balance sheet, not the business. With trailing P/E at -1.39 and no EV/EBITDA observable, valuation rests entirely on residual assets rather than earning power, per current market data.
The 7.39x price-to-sales multiple looks superficially in line with pre-commercial biotech peers, but because TRDA's quarterly revenue has collapsed to under $1M, this ratio reflects an eroding denominator rather than a rich growth premium; investors should treat it as near-meaningless. The 0.65x P/B discount to peers such as NTLA (2.15x) and BEAM (2.30x) may indicate the market prices TRDA's cash-heavy balance sheet with a governance or durability haircut rather than assigning franchise value to its intracellular therapeutic platform.
Returns Swing From Compounder to Destroyer
ROIC collapsed from +13.9% in 2024Q2 to -15.8% in 2026Q2, with ROE following the same path from +15.7% to -17.0%, based on Entrada's reported quarterly ratio disclosures. The reversal appears episodic rather than cyclical, tied to a one-time revenue event.
The 2024 profitability spike coincided with the $94.7M revenue quarter that has not recurred, so the historical ROIC peak should not be read as evidence of a durable moat; on the current cost structure of roughly $46M quarterly operating expense against sub-$1M revenue, every dollar of capital deployed is producing negative returns. The persistence of double-digit negative ROIC across eight of ten quarters suggests the business is decaying capital rather than compounding it, and any recovery thesis hinges on pipeline economics that the ratio data cannot confirm.
Receivables Lengthen as Sales Vanish
DSO ballooned from 8 days in 2024Q4 to 157 days in 2026Q2 while asset turnover flatlined at 0.00, per Entrada's quarterly ratio reporting. Longer collection periods against a shrinking revenue base imply receivable quality and recoverability warrant closer diligence.
A 157-day DSO alongside immaterial revenue suggests the receivables balance is stale relative to current billings, potentially representing milestone or royalty amounts with collection timing outside management's control; analysts should test this against allowance disclosures. The near-zero asset turnover confirms the company's $298.9M asset base is effectively idle in commercial terms, meaning efficiency ratios offer no offset to the burn — the assets are being consumed, not deployed.
High Current Ratio Belies Short Runway
TRDA's current and quick ratios both stand at 10.89 in 2026Q2, identical figures that signal almost no inventory dependence, yet against roughly $42M of quarterly operating losses this liquidity buffer appears to translate to only two-to-three quarters of runway, as inferred from reported financial statements.
The absence of a gap between current and quick ratios indicates TRDA's current assets are almost entirely cash and receivables, which is favorable for liquidation quality but means the buffer has no operational ballast. The stress test is straightforward: with a debt-to-equity ratio of just 0.21 and modest absolute debt near $48.5M, refinancing is not the binding constraint — equity issuance on dilutive terms appears more likely, and the falling cash base should be monitored against the burn rate disclosed in cash flow filings.
Low Leverage Offers Limited Signal
Debt-to-equity eased from 0.25 in 2024Q1 to 0.21 in 2026Q2, with interest coverage unavailable across all periods presented, according to Entrada's quarterly disclosures. Minimal leverage provides strategic flexibility but says little about creditworthiness when operations consume cash at the current pace.
Because the D/E ratio of 0.21 sits below most listed genetic-medicine peers — NTLA at 0.14 is comparable, but ARWR at 0.73 and EDIT at 2.81 carry more debt — TRDA's low leverage appears to reflect a choice enabled by prior capital raises rather than superior cash generation, and the declining absolute debt load is consistent with scheduled repayment from a shrinking asset base. The absence of coverage and D/EBITDA data means solvency cannot be assessed conventionally; investors should instead anchor on cash runway and covenant terms in debt filings.
Price-to-Book Is the Trap Multiple Here
The 0.65x P/B is the ratio most likely to mislead on TRDA, since its book value is almost entirely funded shareholder cash rather than accumulated operating earnings, per reported balance sheets. A sub-1x reading on such a base reflects run-off risk, not value.
In biotechnology platforms, book value accumulates from successive equity raises, so a low P/B typically signals the market's expectation that capital will be burned before it earns — precisely the dynamic TRDA's -17% ROE and persistent negative FCF margins illustrate, rather than a classic deep-value setup. A more informative alternative is enterprise value relative to remaining cash and pipeline stage, or a scenario-weighted value of partnership and milestone potential, which would force explicit assumptions about a revenue base that has already contracted by over 99% from its 2024 peak.